Cyclooxygenase-2 Expression in Primary and Recurrent Pterygium

Adigüzel, Ufuk; Karabacak, Tuba; Sarı, Alper; O, Oz; Cinel, Leyla

doi:10.1177/112067210701700602

Cited by 18 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, some studies have reported that the formation and development of pterygium are associated with vascular endothelial growth factor (VEGF), cyclo-oxygenase (COX), and multiple proinflammatory cytokines (e.g., interleukin-6, interleukin-8) (Adiguzel et al, 2007;Park et al, 2011;Martín-López et al, 2019). Some researchers have used subconjunctival injections of anti-VEGF drugs as adjuvant therapy to treat pterygium and have achieved favourable outcomes (Singh et al, 2015;Mohamed et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

et al. 2021

View full text Add to dashboard Cite

Purpose: To evaluate the effect of a topical nonsteroidal anti-inflammatory drug (0.1% pranoprofen) on the expression of VEGF and Cox-2 in primary pterygium.Methods: This was a prospective, randomized study. Between January 2019 and April 2020, 120 patients diagnosed with primary pterygium were enrolled and randomly divided into three groups before operation: 1) 40 patients in group 1 received topical pranoprofen 0.1% four times daily for 4 weeks, 2) 40 patients in group 2 received topical fluorometholone 0.1% four times daily for 4 weeks, and 3) patients in group 3 did not receive treatment. For each group, the age, sex, eye type, best-corrected visual acuity (BCVA), intraocular pressure (IOP), duration of onset, combined systemic diseases, and the results regarding vascular endothelial growth factor (VEGF) and cyclo-oxygen-ase-2 (COX-2) in postoperative pterygial tissues were evaluated in detail.Results: There were no significant differences regarding age, sex, eye type, combined systemic diseases, duration of onset, IOP, and BCVA within the three groups (p > 0.05). The reduction of VEGF and CoX-2 expression of pterygial vascular endothelial cells in group 1 were statistically significant compared to group 2 and group 3 (p < 0.05). There were significant correlations between COX-2 and VEGF expression of pterygial tissues within the three groups (p < 0.05).Conclusion: The present findings suggested that the topical pranoprofen 0.1% could reduce the expression of VEGF and COX-2 in primary pterygium. We confirmed that treatment with pranoprofen offers advantages in early intervention and has therapeutic potential in reducing the postoperative recurrence of primary pterygium patients.Clinical Trial registration: The study was registered with the Chinese Clinical Trial Registry. (http://www.chictr.org.cn/index.aspx, Registration Number: ChiCTR2100047726).

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Ho we ver, we eva lu a ted the ex pres si on of COX-2 only in non-inf la med pterygi um tis su es sin ce we usu ally tre at the se ca ses with a co ur se of to pi cal an ti-inf lam ma tory agents since we assume that excising the ptery gi um at its inflam ma tory sta ge might in cre a se pos to pe ra ti ve comp li ca ti ons and re cur ren ce ra tes. COX-2 expres si on was fo und to be in cre a sed in re cur rent ptery gi um ca ses in stu di es by Ka ra han et al 24 and Adı gu zel et al 25 Ho we ver, our study de mons trated that the ex pres si on of COX-2 is not ele va ted in non-inf lam med pri mary and re cur rent ptery gi um ca ses. Furt her, in cli ni cal prac ti ce, to pi cal ste ro ids or NSA IDs usu ally pro vi de only tem po rary re li ef in the se ca ses wit ho ut any sig ni fi cant be ne fit in terms of hal ting the di se a se pro cess.…”

Section: -22mentioning

confidence: 59%

Expression of Cyclooxygenase-2 and Ki-67 in Primary and Recurrent Pterygias

Konuk¹,

Aktaş²,

Erdem³

et al. 2011

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To evaluate the expression of cyclooxygenase-2 (COX-2) and Ki-67 in primary and recurrent pterygia. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Pterygium excision together with limbal/conjunctival autografting was performed in primary and recurrent pterygium cases who did not have clinically evident inflammatory findings. The excised tissues were stored at -80 °C for the analysis. Ki-67 expression was determined with only immunohistochemically while COX-2 expression was determined with both immunohistochemistry and real-time polymerase chain reaction, which is a more sensitive method. Normal human conjunctival samples from age-matched donors were used as controls. R Re es su ul lt ts s: : Twelve primary and nine recurrent pterygium tissues were included in the study group. The expression of COX-2/β actin mRNA was not significantly different in primary pterygia, recurrent pterygia and normal conjunctival tissues (0.0082±0.0038, 0.0094 ± 0.0023, and 0.0075 ± 0.0035 respectively (p=0.32). The expression of Ki-67 nuclear antigen was significantly higher both in primary and recurrent cases when compared to control group (5.2±5.0%, 7.1±2.% and 1.29±0.9% respectively (p=0.018 and p= 0.001, respectively). There was no significant correlation between immunohistochemical expression of Ki-67 and COX-2 in primary and recurrent pterygium tissues (p=0.281, r=0.339; p=0.649, r=-0.177, respectively. C Co on nc cl lu us si io on n: : COX-2 expression does not seem to increase in clinically uninflamed primary and recurrent pterygia tissues. Increased Ki-67 expression in primary and recurrent pterygia supports the proliferative nature of the disease which might have implications in regard to treatment options. K Ke ey y W Wo or rd ds s: : Pterygium; Cyclooxygenase 2; Ki-67 antigen Ö ÖZ ZE ET T A Am ma aç ç: : Primer ve nüks pterjiyumda siklooksijenaz-2 (COX-2) ve Ki-67 ekspresyonunun değerlendirilmesi. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : İnflamatuvar bulguları olmayan, primer ve nüks pterjiyum olgularında, limbal konjonktival otogreft yöntemi ile pterjiyum cerrahisi uygulandı. Tüm dokular analiz için -80 °C'de saklandı. Bu dokularda Ki-67 ekspresyonu sadece immünohistokimyasal olarak incelenirken; COX-2 ekspresyonu hem immünohistokimyasal olarak, hem de daha duyarlı bir analiz yöntemi olan gerçek zamanlı polimeraz zincir reaksiyonu yöntemi kullanılarak değerlendirildi. Pterjiyum dokularındaki Ki-67 ve COX-2 ekspresyon düzeyleri, sağlıklı konjonktival dokulardaki ekspresyon düzeyleri ile karşılaştırıldı. Tüm gruplarda Ki-67 ve COX-2 düzeyleri arasındaki korelasyonlar değerlendirildi. B Bu ul lg gu ul la ar r: : On iki primer ve dokuz rekürren pterjiyum olgusu çalışmaya dahil edildi. Ortalama COX-2/β aktin mRNA ekspresyonu primer, nüks pterjiyum ve kontrol konjonktiva dokularında sırasıyla 0.0082±0.0038, 0.0094±0.0023 ve 0.0075 ± 0.0035 idi (p=0.32). Ortalama Ki-67 nükleer antijen immünopozitifliği primer ve nüks pterjiyum dokularında kontrol ...

show abstract

“…Chiang et al found that more than 80% of pterygium tissue studied showed positive expression of COX-2 in the epithelium; however, they found no COX-2 expression in the stroma (24). Subsequent studies by Adigüzel et al (25), Karahan et al (26), and Maxia et al (27) reported COX-2 expression in the epithelium of primary pterygia in 60%, 84.2%, and 67.7% of the cases, respectively. Karahan and Maxia also reported COX-2 expression in the stroma.…”

Section: Discussionmentioning

confidence: 99%

Chemokine CXCR-4 and cyclooxygenase-2 in the pathogenesis of pterygium

Baser¹,

Sivrikoz²,

Karahan³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: This study aimed to investigate the expression of chemokine receptor 4 (CXCR-4) and cyclooxygenase-2 (COX-2) in the epithelium and stroma of pterygium tissue in comparison with healthy conjunctiva. Materials and methods:The expression of CXCR4 and COX-2 was investigated by immunohistochemistry in the epithelium and stroma of the pterygium tissue of 29 eyes and compared with healthy conjunctival tissues. The correlation between CXCR4 and COX-2 expression as well as the correlation of these markers with the area of pterygium were evaluated statistically.Results: COX-2 staining scores were 1.75 ± 0.63 in the epithelium and 1.20 ± 0.62 in the stroma of the pterygium tissue. Mean CXCR-4 staining in the epithelium was 0.069 ± 0.37, whereas it was 5.0 ± 2.84 cells in the stroma. There was almost no staining of COX-2 and CXCR4 in the control samples. There was a strong positive correlation between the expression of CXCR-4 and COX-2 in the stroma of the pterygium. Conclusion:CXCR-4 and COX-2 may play important roles in the pathogenesis of pterygium.

show abstract

Cyclooxygenase-2 Expression in Primary and Recurrent Pterygium

Abstract: COX-2 expression is increased in recurrent pterygium tissues and COX-2 expression may be a marker for the prediction of recurrence.

Cited by 18 publications

References 35 publications

Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

Expression of Cyclooxygenase-2 and Ki-67 in Primary and Recurrent Pterygias

Chemokine CXCR-4 and cyclooxygenase-2 in the pathogenesis of pterygium

Contact Info

Product

Resources

About